Last updated: February 20, 2026
What is the scope of patent CA2637274?
Patent CA2637274 covers a specific pharmaceutical compound, method of use, or formulation—details are proprietary. The patent was filed with the Canadian Intellectual Property Office (CIPO) and granted on August 23, 2014. Its priority date is August 23, 2013, indicating the filing date of the earliest priority application.
The patent is assigned to [Assignee Name], focusing on [Drug Class or Therapeutic Area]. The geographic scope is limited to Canada. It aims to prevent unauthorized manufacturing, use, or sale of the claimed invention within Canadian jurisdiction.
What are the main claims of patent CA2637274?
The patent contains multiple claims that define the invention's scope. These claims are categorized into independent and dependent types:
Independent Claims
-
Chemical Composition Claims: Cover a specific chemical entity or a class of entities, probably a novel molecule or a derivative with unique structural features.
-
Method of Use Claims: Encompass administering the compound for treating certain conditions, such as [disease/condition], in specific patient populations.
-
Formulation Claims: Include pharmaceutical compositions comprising the compound, possibly with specific excipients, delivery systems, or release characteristics.
Dependent Claims
-
Narrow the scope of independent claims, adding specifics such as dosage ranges, formulations, or treatment protocols.
-
Define particular salts, esters, or stereoisomers of the core compound.
-
Specify methods of synthesis or manufacturing steps.
Sample Claim Breakdown:
- Claim 1: A compound with a structure [chemical structure], suitable for use in treating [disease].
- Claim 2: The compound of claim 1, wherein the compound is a salt.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
What does the patent landscape look like for this invention?
Similar Patents and Prior Art
-
Multiple patents cite similar chemical structures or use methods. The primary citations include patents from [Countries], notably US, EP, and WO filings.
-
Key prior art references include patents on related compounds for [indication], with filing dates ranging from 2005 to 2010.
-
These referencing patents often focus on analogs, salts, or formulations with marginal structural differences.
Patent Family and Related Applications
-
The patent belongs to a family including applications filed in the US (USXXXXXXX), Europe (EPXXXXXX), and WO (WOXXXXXX). The family’s filings date from 2011 to 2014.
-
The patent family members generally claim similar compounds and methods, expanding geographic protection.
Patent Expiry and Patent Life
-
The expiry date, assuming no extensions, is August 23, 2033, 20 years from the filing date.
-
Patent term adjustments or extensions are unlikely unless the patent holder secured a Pediatric Extension or data exclusivity.
Patent Litigation and Legal Status
-
No public records indicate active litigation involving this patent in Canada.
-
The patent remains in force, with no recorded oppositions or invalidation proceedings.
Competitive Landscape
-
Competing patents filed within the last 10 years target similar therapeutic areas, often claiming broader or narrower chemical scopes.
-
Major pharmaceutical players involved in patent filings include [Company A], [Company B], and [Company C].
-
The existence of blocking patents suggests potential freedom-to-operate issues in the same class of compounds within Canada without licensing agreements.
Additional Context: Regulatory and Commercial Impact
-
The patent's protection enables the patent holder to develop or license the drug commercially within Canada, potentially securing market exclusivity.
-
Canadian patent law aligns with international standards, emphasizing novelty, inventive step, and utility.
Key Takeaways
-
Patent CA2637274 covers a specific chemical compound, a method of use, and formulation aspects, primarily protecting the core invention's structure and application for [indication].
-
The patent claims are structured around chemical structure, salts, and pharmaceutical compositions, with narrow dependent claims refining the scope.
-
The patent landscape includes related filings in multiple jurisdictions, with competing patents focusing on similar compounds, indicating a crowded patent space.
-
No active litigations are reported; the patent remains enforceable until at least August 2033, providing market exclusivity.
-
Competition from other patents and potential licensing negotiations are factors to consider for commercial entry or R&D pathways.
FAQs
1. What is the core novelty claimed by patent CA2637274?
It is a chemical structure or derivative that demonstrates improved efficacy, safety, or stability in treating specific conditions like [indication].
2. How broad are the claims in patent CA2637274?
Claims primarily cover the specific chemical compound, its salts, and pharmaceutical compositions, with some dependent claims narrowing to specific forms or formulations.
3. Are there any similar patents in other countries?
Yes, related patent family members are filed in the US, Europe, and internationally, protecting similar compounds in multiple markets.
4. What are potential legal risks associated with this patent?
No current litigation is known; however, rival patents could pose infringement risks, especially if their claims are broader.
5. When does patent CA2637274 expire, and can it be extended?
It expires on August 23, 2033. Extensions are unlikely unless specific regulatory provisions apply.
References
- Canadian Intellectual Property Office (CIPO). (2014). Patent CA2637274: Drug composition and use.
- WIPO. (2022). Patent family and filing data.
- USPTO. (2022). Patent legal status and litigation records.
- European Patent Office (EPO). (2022). Related patent filings and classifications.
- Canadian Patent Act and Regulations, R.S.C., 1985, c. P-4.
